You are here

Press Release Archive

- Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

(BUSINESS WIRE) Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by significantly reducing the risk of cardiovascular events in patients with heart disease, according to two separate economic analyses. The data were presented at the annual meeting of the American College of Cardiology. “One of these analyses suggests that even with the availability of low

- Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients

(BUSINESS WIRE) Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent reduction in stroke in patients with type 2 diabetes and metabolic syndrome but without heart disease. In a separate study, patients who had suffered a recurrent stroke or mini-stroke during the trial had a significant 53 percent reduction in the risk of major coronary events (death from cardiac causes, heart

- Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis

(BUSINESS WIRE) Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting of

- Pfizer Announces Launch of Generic Amlodipine Besylate Product by Greenstone

(BUSINESS WIRE) In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company’s Greenstone subsidiary. Norvasc also will remain available to patients. Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six

- Pfizer to Present New Lipitor Data, Including Results from Three Large Atherosclerosis Imaging Trials, at the American College of Cardiology Meeting

(BUSINESS WIRE) Pfizer announced today that new data regarding the effect of Lipitor (atorvastatin calcium) on atherosclerosis, cardiovascular events such as heart attacks and strokes, and health economics will be presented next week at the American College of Cardiology annual meeting in New Orleans. Atherosclerosis Imaging Trials Three large imaging studies compared Pfizer’s former investigational compound

- Pfizer Statement in Response to Appeals Court Decision in Norvasc Patent Case

(BUSINESS WIRE) Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the company’s U.S. patent covering amlodipine besylate, the active ingredient in Norvasc. Pfizer is reviewing the decision and is considering all its options, including seeking reconsideration. Generic manufacturer Apotex filed the appeal after a lower

- Pfizer Wins Celebrex Patent Challenge by Generic Manufacturer Teva

(BUSINESS WIRE) Pfizer Inc announced today that a federal court in the District of New Jersey (Newark) has upheld the three main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. Judge John C. Lifland ruled that the patents (Nos. 5,466,823; 5,563,165


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.